|
Match
|
Document |
Document Title |
|
|
7378423 |
Pyrimidine compound and medical use thereof
The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]
wherein each symbol is as defined in the...
|
|
|
7304062 |
Peroxisome proliferator activated receptor alpha agonists
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or...
|
|
|
7232820 |
Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
The present invention relates to compounds of the Formula I
wherein R 1 , R 3 , R 5 , R 7 , X, Y and U are as defined. Compounds of the Formula I have activity inhibiting production of...
|
|
|
7226921 |
Compounds and compositions as cathepsin S inhibitors
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
|
7226920 |
Aminotriazole compounds useful as inhibitors of protein kinases
The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the...
|
|
|
7220745 |
Heterocyclic compounds useful to treat HCV
The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the...
|
|
|
7173030 |
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
The present invention relates to compounds with the formula (I)
and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for...
|
|
|
7169768 |
Method of decreasing atherosclerosis and its complications
A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease wherein the method involves administering to...
|
|
|
7091203 |
Imidazo[1,3,5]triazinones and their use
The invention relates to imidazo[1,3,5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
|
|
|
7084139 |
Pyrrolidin-2-one derivatives as inhibitors of factor Xa
The invention relates to compounds of formula (Ic)
processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the...
|
|
|
7074788 |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
The present invention relates to compounds with the formula (I)
and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for...
|
|
|
7064123 |
Compounds and compositions as cathepsin inhibitors
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
|
7045520 |
Opioid receptor active compounds
The invention provides compounds of formula I:
wherein R 1 to R 4 and n have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also...
|
|
|
7030149 |
Combination of brimonidine timolol for topical ophthalmic use
Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for...
|
|
|
7022705 |
Isoxazoline derivatives useful as antimicrobials
Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,
wherein, for example,
HET is an N-linked 5-membered, fully or partially...
|
|
|
6956037 |
Benzamide derivatives for the treatment of diseases mediated by cytokines
The invention concerns amide derivatives of Formula (I), wherein R 3 is (1-6C)alkyl or halogeno; m is 1-3 and R 1 is selected from substituents such as: (A) hydroxy, halogeno, (1-6C)alkyl,...
|
|
|
6949518 |
Methods for treating macular degeneration with topiramate
A method for treating macular degeneration and/or treating optic nerve degeneration of a patient comprises administering topiramate with a dosage pharmaceutically effective to suppress degeneration...
|
|
|
6894046 |
IL-5 inhibiting 6-azauracil derivatives
The present invention is concerned with the compounds of formula
the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein p is 0 to...
|
|
|
6852719 |
Glucocorticoid receptor modulators
The present invention provides non-steroidal compounds of Formula I, including prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial...
|
|
|
6841551 |
Brain, spinal, and nerve injury treatment
A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use...
|
|
|
6821972 |
3-heterocyclylpropanohydroxamic acid PCP inhibitors
Compounds of formula (I): and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a...
|
|
|
6803365 |
Imidazo&lsqb 1,3,5&rsqb triazinones and the use thereof
The invention relates to imidazo[1.3.5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
|
|
|
6730671 |
Compounds useful as reversible inhibitors of cathespin S
Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are...
|
|
|
6723742 |
Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R 1 -R 5 are as defined in the description. The compounds have useful pharmaceutical properties and are...
|
|
|
6686388 |
Regulators of the hedgehog pathway, compositions and uses related thereto
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function...
|
|
|
6649614 |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or...
|
|
|
6642234 |
Acrylonitrile compounds
The present invention relates to acrylonitrile compounds of formula (1): [wherein, R is a C 1 -C 6 alkyl, a C 3 -C 7 cycloalkyl optionally substituted by a C 1 -C 4 alkyl, a naphthyl, etc., R...
|
|
|
6638930 |
Morpholine and thiomorpholine tachykinin receptor antagonists
Substituted heterocycles of the general structural formula: are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium...
|
|
|
6630468 |
Disubstituted pyrazolines and triazolines as factor Xa inhibitors
The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M 1 and M 2 maybe N and D...
|
|
|
6624165 |
Cyclopentene derivatives useful as antagonists of the motilin receptor
The compounds of formula I are useful in treating gastrointestinal disorders associated with antagonizing the motilin receptor. The compounds compete with erythromycin and motilin for the motilin...
|
|
|
6613765 |
Use of NK-1 receptor antagonists for treating major depressive disorders
The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and...
|
|
|
6608057 |
Compounds useful as reversible inhibitors of cathepsin S
Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are...
|
|
|
6593094 |
Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
Optimal ratios of pharmaceutical compositions of β-1 and β-2 agonists with their respective antagonists. Safer, more cost-effective drugs for heart and lung therapies are made by combining...
|
|
|
6586478 |
Methods and compositions for improving sleep
Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.
|
|
|
6583142 |
Polymorphic form of a tachykinin receptor antagonist
This invention is concerned with a novel polymorphic form of the compound...
|
|
|
6579872 |
Bezamide derivatives for the treatment of diseases mediated by cytokines
The invention concerns the use of amide derivatives of formula (I) wherein: R 1 and R 2 are substituents such as hydroxy, C 1-6 alkoxy, mercapto, C 1-6 alkylthio, amino, C 1-6 alkylamino and...
|
|
|
6573261 |
Method for treating or preventing psychosomatic and psychoimmunologic disorders
This invention relates to the use of a tachykinin receptor antagonist for treating a psychosomatic or a psychoimmunological disorder in a patient.
|
|
|
6541500 |
Fungicide mixture
Fungicidal mixtures, comprising as active components a) a compound of the formula I its N-oxide or one of its salts where: R 1 , R 2 , R 3 , R 4 independently of one another are: hydrogen,...
|
|
|
6500827 |
Drug combinations
This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients...
|
|
|
6495608 |
Methods of performing surgery with galactomannan polymers and borate
The present invention is directed to viscoelastic systems comprising a combination of a galactomannan polysaccharide containing composition and borate containing composition. The two compositions...
|
|
|
6417187 |
1,2,4-triazole based compounds that can be used as insecticides or acaricides and processes
3-(Substituted aryl)-5-{substituted aryl-(alkynyl-aryl)}-[1,2,4]- triazole compounds are useful as insecticides and acaricides. New synthetic procedures and intermediates for preparing the...
|
|
|
6403593 |
Triazole compounds and the use thereof
The present invention relates to triazole compounds of the following formula: where R 1 , R 2 , A, B and Ar have the meanings stated in the description. The compounds according to the invention...
|
|
|
6399605 |
Ophthalmic composition comprising a beta -blocker
The invention concerns an ophthalmic composition comprising a beta-blocker solution, said composition being obtained by dissolving in water beta-blocker in the presence of alginic acid and adding...
|
|
|
6372729 |
Trisubstituted 1,3,5,-triazine derivatives
This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR 4 ...
|
|
|
6319953 |
Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist
The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and fluoxetine.
|
|
|
6316443 |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
Combinations of a β-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently...
|
|
|
6313111 |
Substituted 6H-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and pharmaceutical composition containing them
Substitued 6H-1,3,4-thiadiazin-2-amines of the following general formula: ##STR1## wherein Ar is phenyl optionally substituted with one or more chloro, bromo atoms, C 1 -C 4 alkoxy, or C 1 -C 4 ...
|
|
|
6300356 |
Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in...
|
|
|
6297241 |
Carbamate derivatives of diaryl 1,3,4-oxadiazolone
The present invention provides novel carbamate oxadiazolone derivatives having the general formula ##STR1## wherein R 1 and R 2 are as defined herein, or a nontoxic pharmaceutically acceptable...
|
|
|
6297240 |
Method for treating ophthalmic disease through fast dispersing dosage forms
This invention relates to pharmaceutical compositions for oral administration comprising a carrier and, as active ingredient, an ophthalmologically active compound, characterized in that the...
|